Led · Equity · Aug 2025

Aragen Life Sciences operates as a contract research, development and manufacturing organization (CRDMO) offering end‑to‑end services from discovery through commercialization, including recent biologics and ADC capabilities. The company recently completed qualification of a biologics manufacturing facility, with first GMP batches scheduled for late July 2025 and the first phase having become operational in December 2024 to support Phase 2 trials and beyond. Aragen is expanding its India operations, announcing a planned ₹2,000 crore investment in Telangana that is expected to create 1,500 jobs. Management is pursuing both organic capacity expansion and selective acquisitions while pushing international market penetration. The firm is preparing for a potential IPO and has strategic financial backing from investors to support that path. Following a $100M investment from Quadria Capital that values the company at about $1.4B, Aragen has strengthened its position in the competitive CRDMO market and is positioning to capture growing biologics outsourcing demand. Aragen Life Sciences is a contract research organization and contract development and manufacturing organization offering outsourced discovery, development and manufacturing services across small- and large-molecule platforms. The company serves a worldwide customer base including the United States, Europe and Japan and has built deep domain expertise and strong global delivery capabilities. Aragen has demonstrated strong organic growth and partnerships with global biopharmaceutical and biotech clients. The business operates across seven sites in India and overseas, employs over 3,000 professionals, and serves more than 450 life-sciences customers. Recently the company sold a significant minority stake to Goldman Sachs through a purchase of shares held by ChrysCapital and other existing shareholders. Management and Goldman Sachs plan to expand Aragen’s portfolio of differentiated offerings and client base to accelerate growth and move toward becoming a leading global end-to-end drug discovery and development provider.

Led · Equity · May 2024

NephroPlus is described in the article as India’s largest dialysis chain that provides dialysis services. The article identifies the company primarily by its core service offering—dialysis care through a chain of centers. No founding year, revenue, user counts, or other operating metrics are disclosed in the article. The piece focuses on a recent investment event rather than operational detail or explicit future plans for the company. The article does not specify any strategic initiatives, expansion plans, or changes to management resulting from the investment. Financially, the only disclosed item is the $102 million minority-stake investment by Quadria Capital. NephroPlus is a Hyderabad-based provider of dialysis services that operates its own centres and partners with hospitals and state governments. In the last two years it added 80+ centres in India and entered the Philippines market via acquisition of Royal Care Dialysis. The company secured a $100 million dialysis contract in Uzbekistan, which includes building the world’s largest dialysis centre in Tashkent. It has signed up 200+ reputed hospitals as partners, including Fortis Hospitals, CARE Hospitals, Medanta and Max Healthcare, and operates PPP centres and the country’s largest dialysis centre at Tirupati. Management says it will use new capital to drive organic and inorganic growth in India and overseas and to build a digital health solution targeted at dialysis patients. Leadership noted the company faced challenges during COVID but strengthened its position through scale, customer connect and backward integration on costs. NephroPlus operates a widespread dialysis services network, describing itself as a cost-effective, easy-to-use dialysis provider. Founded about a decade ago by Vikram Vuppula and Kamal Shah, the company reports presence across 20 states with 196 centres and a dialysis network in around 125 locations. Financially, it logged a turnover of Rs 200 crore in 2018–19 and expected to end the current fiscal at about Rs 270 crore. The company plans to use new funding for India expansion via select acquisitions and centre openings, plus overseas expansion into the Middle East and Southeast Asia. Management also intends to establish joint ventures and sign operations and maintenance contracts as part of its growth strategy. Earlier backers include Bessemer Venture Partners, SeaLink Capital and the IFC. NephroPlus operates a network of outpatient dialysis centres, providing dialysis services across India. As of the article it had 75 centres across 15 states and has signed a contract to run 13 centres in Andhra Pradesh under the National Dialysis Services Programme. The company plans to expand its network to 500 centres over the next five years and is pursuing growth including acquisitions. Management said the new funding will be used to expand its network. Financially, net sales more than doubled to Rs 30.9 crore in 2014-15 from Rs 13.8 crore the prior year; net loss widened to Rs 6.8 crore but at a slower pace. The firm was founded in 2009 and was still to file its 2015-16 financials at the time of the report. NephroPlus is a start-up providing affordable dialysis care services. It currently operates 26 centres across 10 states and plans to expand its network to 150 centres and reach 20 states within three years. The company says it may pursue a public issue once it crosses a "critical mass" of 100 units. IFC, a World Bank Group member, invested $7 million and Bessemer Venture, a US-based global venture capital firm, invested $3 million, according to the article. Those investments total $10 million and appear intended to fund the planned rapid expansion of centres and geographic reach. The article does not disclose revenues or other operating metrics beyond centre and state counts.

Participated · Equity · Aug 2023

MediBuddy is an Indian digital healthcare platform operating in the healthtech space. The company offers digital healthcare services. It announced it has secured $18 million in funding. The capital came from existing investors Quadria Capital, Lightrock and TEAMFund. The announcement did not disclose the financing instrument, valuation, or operating metrics such as revenue or user counts. No additional future plans or transaction terms were provided in the report. MediBuddy is an end-to-end digital healthcare platform that provides 24x7 access to specialist doctors via video calls, doorstep medicine delivery, at-home lab tests, mental health support and other integrated services. Led by CEO Satish Kannan and based in Bangalore, the platform has catered to the healthcare needs of over 3 crore Indians. The company’s core product integrates telemedicine, diagnostics and pharmacy fulfillment into a single user experience. Following the Series C, MediBuddy plans to invest in customer awareness and hiring. It also intends to strengthen its technology platforms, including data science capabilities, and to fund clinical research and product development. MediBuddy is a digital healthcare platform with a partner network comprising doctors, hospitals, diagnostic centres and pharmacies across India. The company raised Rs 25 crore in a venture debt round led by Stride Ventures. MediBuddy will use the funds to further strengthen its technology, operations and marketing. The financing came as venture debt, not equity. Stride Ventures is a venture debt fund that recently launched its second fund with a target corpus of over Rs 1,000 crore and has disbursed over Rs 200 crore since January. The company operates in the Indian digital healthcare market. MediBuddy is a digital healthcare platform. The company announced it has closed a $40 million Series B funding round. The financing was led by India Life Sciences Fund III, LLC. The round included participation from other, unnamed investors. The announcement was reported in India and provided no additional operational or revenue metrics. No further details on use of proceeds or prior rounds were disclosed in the article. MediBuddy DocsApp, formed by the merger of Bengaluru-based DocsApp and MediBuddy, is a digital healthcare platform providing online specialist doctor consultations, lab tests, preventive health checks and medicine delivery. The joint entity serves over three crore Indians via a partner network of more than 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres and 2,500 pharmacies, covering over 95% of Indian pin codes. It targets both enterprise and retail customers and aims to deliver an on-demand healthcare platform with strong customer experience. The company plans to use new funding to strengthen its doctor base, patient reach, product, and technology. Leadership said the merger will help establish market leadership and advance the mission of providing high-quality healthcare to a billion people.